



Investigator-initiated clinical trials in allergy immunotherapy

The call for applications is now open!

Research field & application process

Background: The aim of allergy immunotherapy is to build tolerance against the allergen, that the patient is allergic to. Tolerance is built over time by giving repeated doses of the responsible allergen. As the patient is being exposed to the allergen, they are allergic to, initially, local allergic reactions can occur, which may influence the patient's adherence to therapy.

Areas of support: ALK aims to further optimise patients' experience and adherence to allergy immunotherapy, when administered as sublingual immunotherapy (SLIT)-tablets. Therefore, ALK is inviting health care professionals to submit proposals for an investigator-initiated trial (IIT), that investigates how local side effects related to SLIT-tablet initiation can be managed in clinical practice, e.g. use of antihistamines.

Application for IIT grant: Submission deadline for IIT proposals is 1-SEP-2023. A total of up to 5 mio DKK is available to support one or more proposals. Proposals including request for funding should be submitted to grant.proposal@alk.net. After internal review of the proposals, information about granted funding, or rejection will be communicated to the applicant by December 2023.

Deadline for applications: 1 September 2023

Proposals including request submitted to:
grant.proposal@alk.net



ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. It markets allergy immunotherapy treatments and other products and services for people with allergy and allergy doctors. Find more information at www.alk.net.

ALK A/S
Bøge Allé 6-8
DK-2970 Hørsholm
Denmark
Tel: +45 45 74 75 76
Fax: +45 45 74 86 90
www.alk.net